Shape Our Content: Take The Reader Survey

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

woman filling in satisfaction engagement survey on laptop
• Source: Shutterstock: Munthita

We value your feedback and suggestions as we look to improve the format of our content and the way it is delivered to you. By completing our customer survey, you can provide your input on essential aspects of content and delivery.

The survey asks about your preferred content formats, such as articles, infographics, podcasts, data trackers and videos; how you access our content, e.g. email, website, PDF, mobile app and RSS; and coverage areas you value or would like to see more of.

We also want to hear about the accessibility and ease of use of our content, as well as your thoughts about features such as AI, audio articles and article translation. The survey results will help us decide what changes to format, delivery, product features and content coverage will be most valuable to you.

The survey should only take seven minutes to complete, and you get the chance to win an Amazon gift voucher just by taking part. The deadline for survey responses is 17 September.

Take the survey

To discuss the editorial content of Scrip at any time, reach out to me at eleanor.malone@citeline.com .

More from Archive

More from Scrip

Atara In Disarray As Shares Sink On Ebvallo CRL

 
• By 

The Pierre Fabre-partnered allogeneic T-cell immunotherapy is already available in Europe but hopes of a US approval have been hit by a complete response letter citing problems at a third-party manufacturing facility.

Trends To Track In India: Deals, Big Pharma GCC Strategy And CAR-Ts In Motion

 

From continuing consolidation on the home market, big pharma appetite to double down on capability centers and notable R&D advances including traction by a second CAR-T cell therapy, the Indian market looks set for an eventful 2025. Scrip spoke to a cross-section of experts to encapsulate some of the key trends in the first instalment of this two-part roundup.

Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline

 
• By 

Low on cash when Pfizer handed back rights to its hemophilia A gene therapy, Sangamo is talking to partners for its Fabry disease gene therapy to fund its two lead programs through proof-of-concept.